复星医药(600196)吸收合并及私有化复宏汉霖这一事项,倒在了复宏汉霖H股类别股东大会上。1月22日晚间,复星医药公告称,上述事项于仅由独立H股股东享有表决权的复宏汉霖H股类别股东大会上未获通过,复宏汉霖将保留H股上市地位。针对这一事项,复星医药方面向北京商报记者回应称,对复宏汉霖私有化议案未能通过表示遗憾,也充分尊重所有股东的决定,复星医药将一如既往地支持复宏汉霖长期健康发展。同时,复星医药拟...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.